Simple and rapid analysis of atenolol and metoprolol in plasma using solid-phase extraction and high-performance liquid chromatography

Determination of Atenolol and Trimetazidine in Pharmaceutical Tablets and Human Urine Using a High Performance Liquid Chromatography-Photo Diode Array Detection Method

A simple RP-HPLC-PDA method for determination of atenolol (ATN) and trimetazidine (TMZ) in human urine and tablets has been developed. Analytes were separated on a Caltrex BI column (125× 4.0 mm, 5 μm) with 25mM potassium dihydrogen phosphate pH 3.3, methanol, and acetonitrile mobile phases. The PDA detector was operated at 210 nm for TMZ and 225 nm for ATN and the flow rate was 1.0 mL/ min. Linearity was obtained over a concentration range of (1.0-100 μg/mL) for both analytes in standard solutions and the method was successfully applied for determination of target analytes in their pharmaceutical tablets. Excellent linearity was also obtained over concentration ranges of (0.25-25 μg/mL) and (0.5-25 μg/mL) in human urine for TMZ and ATN, respectively. A simple liquid-liquid extraction was applied for urine sample clean-up and a gradient method was used for chromatographic separation. The lower limit of quantitation (LOQ) was 0.99 and 0.60 μg/mL for ATN and TMZ, respectively. The limit of detection (LOD) was 0.30 and 0.18 μg/mL for ATN and TMZ, respectively. Inter- and intraday precision and accuracy for ATN were within ±1.89% in pure form and within ±2.85% in urine samples. Inter- and intraday precision and accuracy for TMZ were within ± 3.99% in pure form and within ± 3.19% in urine samples.

A Micromethod for the Quantification of Atenolol in Plasma Using High-Performance Liquid Chromatography With Fluorescence Detection

A simple, rapid, selective, and sensitive analytical method was developed for the quantification of atenolol in small volumes of plasma, by high-performance liquid chromatography with fluorescence detection. Only 200 microL of plasma was used for chromatographic analysis. Separation was performed on a C18 reverse-phase column (4 microm) using a binary mobile phase consisting of 0.05 M of phosphate buffer, pH 5.5, and methanol (80:20, vol/vol) at a flow rate of 0.7 mL/minute. The retention times of atenolol and of the internal standard (sotalol) were 12.7 and 10.4 minutes, respectively. Validation of this analytical method showed a good linear correlation (8-2000 ng/mL), high sensitivity (quantification limit: 8 ng/ml and detection limit: 4 ng/mL), accuracy of 99.3%, and intraday and interday precision of 5.3% and 6.9%, respectively. Absolute recovery was 93.7%. The method was found to be robust, with acceptable stability. The analytical method was validated by the quantification of atenolol in plasma obtained from 2 patients with unstable angina, scheduled for myocardium revascularization surgery, who were chronically treated with 50 mg of atenolol administered per os once a day. The method developed was found to be adequate for use in pharmacokinetic studies and in adjusted dose pharmacotherapy.

Enantioseparation of baclofen with highly sulfated β-cyclodextrin by capillary electrophoresis with laser-induced fluorescence detection

The enantioseparation of baclofen (4-amino-3-p-chlorophenylbutyric acid) was achieved by CE-LIF with highly sulfated beta-CD (HS-beta-CD) as chiral selector. Naphthalene-2,3-dicarboxaldehyde was used for the derivatization of nonfluorescent baclofen. HS-beta-CD (2%) containing 50 mM borate buffer at pH 9.5 was chosen as the optimal running electrolyte and applied to the analysis of baclofen enantiomers in human plasma. The linearity of calibration curves (R2 > or = 0.998) for R-(-) and S-(+)-baclofen was in the 0.1-2.0 microM concentration range. After a simple ACN-protein precipitation, the LOD of baclofen in plasma sample was found as low as 50 nM.

Determination of baclofen enantiomers in pharmaceutical formulations using maltodextrin-based enantioselective, potentiometric membrane electrodes

Two enantioselective, potentiometric membrane electrodes (EPMEs) based on maltodextrins with different value of dextrose equivalent (DE) (maltodextrin I: DE 4.0-7.0; maltodextrin II: DE 16.5-19.5) were proposed for the assay of baclofen enantiomers in baclofen raw materials and from its pharmaceutical formulation, Norton-Baclofen tablets. The slopes of the electrode function of the proposed electrodes were 55.0 mV/pS-baclofen for maltodextrin I-based electrode and 59.0 mV/pR-baclofen for maltodextrin II-based electrode and the detection limits were 1.34 x 10(-6) mol l(-1) (S-baclofen) and 2.52 x 10(-10) mol l(-1) (R-baclofen), respectively. The surfaces of the electrodes are stable and easily renewable by simply polishing on alumina paper.

Simultaneous determination of thirteen β-blockers and one metabolite by gradient high-performance liquid chromatography with photodiode-array UV detection

A new rapid and sensitive high-performance liquid chromatography (HPLC) method has been developed for the simultaneous identification and quantification in human plasma of the 13 most commonly prescribed beta-blockers and one active metabolite-atenolol, sotalol, diacetolol, carteolol, nadolol, pindolol, acebutolol, metoprolol, celiprolol, oxprenolol, labetalol, propranolol, tertatolol and betaxolol. It involves liquid-liquid extraction procedures followed by liquid chromatography coupled to photodiode-array UV detection with a fixed wavelength at 220 nm for quantification. Compounds were separated on a 5 microm Hypurity C(18) (ThermoHypersil) analytical column (250 mm x 4.6 mm, i.d.) using a gradient of acetonitrile-phosphate buffer pH 3.8 at a flow rate of 1.0 ml/min. The total analysis time was 26 min per sample. Extraction recoveries were between 74 and 113% for the polar compounds and between 20 and 56% for the most apolar compounds. Calibration lines were linear in the range from 25 to 1000 ng/ml for all compounds excepted carteolol and nadolol (50-1000 ng/ml), all of them with coefficients of determination (r2 values) >/=0.994. Limits of detection (LODs) ranged from 5 to 10 ng/ml. Intra-assay and inter-assay precision and accuracy were studied at two concentration levels (100 and 500 ng/ml). The intra-assay coefficients of variation (CVs) for all compounds were </= 8.3% and all inter-assays CVs were below 12.6%. The intra-assay and inter-assay accuracies for all compounds were found to be within 91.4 and 105.6% at 100 ng/ml and within 94.1 and 107.4% at 500 ng/ml. Thus, the performance of the method described allows its use in toxicological screening and in quantification of the most prescribed beta-blockers drugs.

Effect of the counter-anion type and concentration on the liquid chromatography retention of beta-blockers

Analysis of beta-blockers, basic pharmaceutical compounds with pKa values greater than 8.5, in reversed-phase HPLC can sometimes be challenging in terms of selection of the mobile phase pH, buffer concentration, and acidic modifier. The effect of the type and concentration of various mobile phase additives on the reversed-phase HPLC retention of these compounds was studied. HPLC analysis was performed at a mobile phase pH of 3 ensuring the protonation of the beta-blockers. It was found that at increasing perchlorate anion concentration at a constant mobile phase pH the retention factor for all beta-blocker compounds studied increased to varying degrees. The relative increase in the retention was attributed to ion interaction with the anionic mobile phase additive. Similar trends were observed when other types of inorganic salts such as NaH2PO4, NaPF6, NaBF4, and CF3CO2Na were employed. Differences in selectivity of the beta-blockers were obtained at a constant pH and an equimolar concentration of the different additives throughout the whole concentration range studied.

Automated liquid chromatographic determination of atenolol in plasma using dialysis and trace enrichment on a cation-exchange precolumn for sample handling

A fully automated method involving dialysis combined with trace enrichment was developed for the liquid chromatographic (LC) determination of atenolol, a hydrophilic beta-blocking agent, in human plasma. The plasma samples were dialysed on a cellulose acetate membrane and the dialysate was reconcentrated on a short trace enrichment column (TEC) packed with a strong cation-exchange material. All sample handling operations can be executed automatically by a sample processor (ASTED system). After TEC conditioning, the plasma sample, to which the internal standard (sotalol, another hydrophilic beta-blocker) was automatically added, was introduced in the donor channel and dialysed in the static/pulsed mode. The dialysis liquid consisted of 4.3 mM phosphoric acid. When the dialysis process was discontinued, the analytes were eluted from the TEC in the back-flush mode by the LC mobile phase and transferred to the analytical column, packed with octyl silica. The LC mobile phase consisted of phosphate buffer, pH 7.0-methanol (81:19; v/v) with 1-octanesulfonate. Atenolol and the internal standard were monitored photometrically at 225 nm. The different parameters influencing the dialysis and trace enrichment processes were optimised with respect to analyte recovery. The influence of two different kinds of cation-exchange material on analyte recovery and peak efficiency was also studied. The method was then validated in the concentration range 25-1000 ng/ml. The mean recovery for atenolol was 65% and the limit of quantitation was 25 ng/ml.

Efficient assay for the determination of atenolol in human plasma and urine by high-performance liquid chromatography with fluorescence detection

An efficient method for the determination of atenolol in human plasma and urine was developed and validated. alpha-Hydroxymetoprolol, a compound with a similar polarity to atenolol, was used as the internal standard in the present high-performance liquid chromatographic analysis with fluorescence detection. The assay was validated for the concentration range of 2 to 5000 ng/ml in plasma and 1 to 20 microg/ml in urine. For both plasma and urine, the lower limit of detection was 1 ng/ml. The intra-day and inter-day variabilities for plasma samples at 40 and 900 ng/ml, and urine samples at 9.5 microg/ml were <3% (n=5).

Solid-phase extraction and derivatisation methods for beta-blockers in human post mortem whole blood, urine and equine urine

This paper details various rapid and sensitive methods for the extraction and derivatisation of propranolol, metoprolol, sotalol, atenolol, pindolol, timolol, oxprenolol, alprenolol and penbutolol in equine urine and in human post mortem whole blood and urine. Three solid-phase extraction methods are described involving the use of either XtrackT XRDAH515, Bond Elut Certify or Sep-Pak C18 cartridges. Two derivatisation methods are also described involving the formation of cyclised silyl or pentafluoropropionate derivatives with either chloromethyldimethylchlorosilane or pentafluoropropionic anhydride, respectively. Gas chromatographic-mass spectrometry analysis was carried out in select-ion monitoring mode. All these methods were evaluated using drug-free human post mortem blood, urine and equine urine fortified at various levels with the beta-blockers mentioned above. The application of some of these methods on a forensic case study is also presented. This work does not include samples from equine administration trials of beta-blockers.

A micro liquid chromatographic assay for the determination of plasma-unbound atenolol

An improved high performance liquid chromatographic assay for plasma-unbound atenolol is described. The assay has a wide range (10-5000 ng ml-1) of linearity and a detection limit of 5 ng ml-1 (or 0.1 ng per injection) with acceptable intra- and inter-assay reproducibilities using small volumes of plasma (100 microliters). Following administration of a single dose of atenolol to the rat, nine blood samples were collected over a period of 8 h. These samples were analyzed for atenolol concentrations by a sensitive and specific microbore high performance liquid chromatograph with a photodiode-array detector. This multi-channel detector was used to acquire spectral information on atenolol and demonstrated a superior performance in comparison to all other techniques in that both qualitative and quantitative information were acquired with the system. Because of it sensitivity and applicability to plasma analysis, the assay can be used for pharmacokinetic studies and is valuable in therapeutic drug monitoring.

High-performance liquid chromatography with amperometric detection applied to the screening of beta-blockers in human urine

A high-performance liquid chromatographic method with electrochemical detection has been developed for the determination of six beta-blockers: atenolol, nadolol, timolol, metoprolol, oxprenolol, and alprenolol. The chromatographic separation was performed using a mu Bondapack C18 column, a mobile phase of acetonitrile-water (40:60), containing 5 mM KH2PO4/K2HPO4 proved to be optimal at a 1.3 ml/min flow-rate, and a pH of 6.5. The temperature was optimized at 30 +/- 0.2 degrees C. The amperometric detector, equipped with a glassy carbon electrode, was operated at 1300 mV versus Ag/AgCl in the direct current mode. The method was applied to the determination of these compounds at two concentration levels: ppm and ppb (ng/ml), obtaining relative standard deviations lower than 5% at ppm levels and lower than 10% at ppb levels, and quantitation limits ranging from 15 ppb to 500 ppb. The method was applied to the screening of beta-blockers in spiked urine samples, with a total elution time lower than 12 min, obtaining the best recoveries for timolol and metoprolol (never greater than 93%). These recoveries together with the low limits of quantitation achieved, allows its application to doping analysis in human urine.

Determination of ten beta-blockers in urine by micellar electrokinetic capillary chromatography

beta-Adrenergic blocking agents are of therapeutic value in the treatment of migraine and various cardiovascular disorders (angina pectoris, cardiac arrhythmia, hypertension). Owing to their sedative effect, they are also used as doping agents in sport. A characteristic feature of beta-blockers is the alkanolamine side-chain terminating in a secondary amino group. The pKa values vary from 9.2 to 9.8. Because some beta-blockers are hydrophilic and some lipophilic, simultaneous determination is difficult. In this work, a method based on micellar electrokinetic capillary chromatography (MECC) was developed for the separation and determination of beta-blockers. The 0.08 M phosphate buffer (pH 7.0) solution contained 10 mM N-cetyl-N,N,N-trimethylammonium bromide (CTAB). Ten parent beta-blockers in human urine could be separated in a single run and determined quantitatively by the internal standard (2,6-dimethylphenol) method. Neither endogenous compounds in urine nor caffeine and its metabolites interfered with the analysis. The clean-up procedure for urine consisted of a simple filtration through 0.5-microns PTFE membranes. The MECC method exhibited good repeatability and a linear range of 25-150 micrograms/ml. The method was applied to determination of oxprenolol in real samples.

Fundamental studies in reversed-phase liquid-solid extraction of basic drugs; I: Ionic interactions

Seven basic solutes with known and controlled pKa (7.93-9.5) and log P (0.23-6.63) values have been used as test probes to study the mechanism involved in liquid-solid extraction with C2 and C18 bonded silica phases. A limited comparison has also been made with underivatized silica and CN phases. In addition to the reversed-phase mechanism, cation-exchange was shown to play a very significant role in the retention process. Various cations both organic and inorganic were assessed for their elution strength, and the ordering was similar to that for classical ion-exchange chromatography. Control of selectivity in the elution process can be achieved by varying the concentration of cation or methanol in the eluent. The C2 cartridge in combination with an aqueous ammonium acetate-methanol eluent proved to be the most versatile in that all compounds, irrespective of pKa or log P could be recovered in high yield. The optimal eluent in terms of selectivity with respect to related compounds could be predicted from the solute log P. Blocking of silanols by pre-conditioning the cartridges with cations prior to sample applications was also studied. The order of cation strengths although somewhat variable was similar to that established at the elution stage. To achieve quantitative elution with methanol or aqueous methanol solutions however, high concentrations of inorganic cations, equivalent to 1 ml of a 1 M solution were required to pre-condition a 100 mg cartridge.

Chromatography of beta-adrenergic blocking agents

The determination of beta-blockers has posed pharmaceutical analysts with a variety of problems arising from the essential characteristics of these compounds as bases and the variability of physicochemical properties of individual drugs. Liquid chromatography has become the favoured method of analysis and to a certain extent there is a standardised approach to analysis based on either solvent or solid-phase extraction and reversed-phase high-performance liquid chromatography coupled to fluorescence detection. The analyst must be aware of interactions occurring during extraction stages. All manipulations should be fully evaluated for individual drugs and metabolites prior to use. Other analytical options are chosen for specific or more demanding applications. The use of unmodified silicas for the liquid chromatography of beta-blockers (and other basic drugs) is an example of a potential alternative mode of chromatography. The stereoselectivity of the pharmacology of beta-blockers has spawned a great deal of literature describing the resolution of enantiomers by chromatographic methods. It is envisaged that this area will achieve greater prominence in the future as drug development pursues optical purity. The demand for the availability of enantiomerically pure pharmaceutical preparations will certainly see developments for preparative-scale separations as well as analytical methods and will surely promote developments in new and established methods of chromatography.

Coupled-column chromatography on immobilized protein phases for direct separation and determination of drug enantiomers in plasma

Columns packed with immobilized alpha 1-acid glycoprotein and albumin were used in coupled-column chromatography to increase their utility for determining low concentrations of enantiomers in biological samples. The two enantiomers eluted from the protein columns were trapped and compressed on two separate columns, packed with hydrophobic stationary phase, and subsequently transferred to a fourth column for final separation. The overall effect was an increase in efficiency and selectivity. Examples are given of separations of the enatiomers of terbutaline, metoprolol, oxazepam and bupivacaine in plasma. For quantitative determination a single calibration can be used for both enantiomers.

High-performance liquid chromatographic determination of beta-adrenoceptor blocking agents in body fluids

Several reports have been published reviewing high-performance liquid chromatographic (HPLC) methods for the determination of beta-adrenoceptor blocking agents (beta-blockers) in biological materials (Flouvat et al., 1981; Mehta, 1983; Marko and Soltés, 1984; Ahnoff et al., 1985; Tkaczyková and Safarík, 1987). Of these, the paper by Mehta (1983) briefly summarizes the interrelationship between physiocochemical properties of beta-blockers with prechromatographic treatment of biological samples, as well as with the HPLC methods used for the determination of 12 beta-adrenoceptor blocking drugs. The work by Ahnoff et al. (1985) concerning the monitoring of cardiovascular drugs also deals with HPLC assays of 18 beta-blockers in plasma. The Appendix to this report presents the great majority of HPLC methods for determining 30 beta-blockers in various body fluids. HPLC methods providing resolution and determination of individual beta-blocker enantiomers have not been included since this topic is being covered by Walle and Walle (1989). The Appendix is just a guide to the methods reviewed for the HPLC determination of parent beta-blockers as well as some of their metabolites co-assayed in various body fluids. It does not include details such as the internal standard, recovery, setting of the detector, limit of determination, etc., given in the individual methods listed. The isolation technique of the drug(s) from the given body fluid represents the main step in the sample work-up procedure. Along with this information, only the type of the HPLC column packing and the detection principle used by each method's developers are given.

Improved screening method for beta-blockers in urine using solid-phase extraction and capillary gas chromatography-mass spectrometry

An improved screening method for beta-blockers in urine is proposed, involving enzymatic hydrolysis, solid-phase extraction and capillary gas chromatography-mass spectrometry. Several extraction methods for beta-blockers, such as conventional liquid-liquid and solid-phase extraction procedures, have been evaluated for at least eight beta-blockers. Additionally, the gas chromatographic properties and mass fragmentation of the trimethylsilyl-trifluoroacetyl, trifluoroacetyl and cyclic n-butylboronate derivatives of beta-blockers have been compared and evaluated with respect to their efficiency for screening urine. The resulting screening method proved to be a specific and sensitive procedure, enabling these analytes to be detected and identified up to 48 h after the administration of a dosage, usually encountered in doping cases.

A strategy for the determination of beta blockers in plasma using solid-phase extraction in combination with high-performance liquid chromatography

This paper describes a general approach for the therapeutic drug monitoring of 13 different beta blockers in plasma. The chromatographic system contains a cyanopropyl-bonded phase as a stationary phase in combination with a mobile phase composed of acetonitrile and phosphate buffer (pH = 3, mu = 0.05). Two modes of detection are used, namely, UV detection and fluorescence detection. The sample pretreatment is performed with a nitrile-sorbent in combination with methanol-phosphate buffer (pH = 3, mu = 0.05) or with methanol containing 0.1% propylamine as eluent. Acceptable recoveries are obtained for practolol, acebutolol, pindolol, oxprenolol, mepindolol, atenolol, propranolol, prenalterol, alprenolol, metoprolol, sotalol and nadolol. For labetalol, however, the elution recovery has to be improved. Finally, this approach is illustrated by the assay of nadolol in the plasma of patients suffering from hypertension, who had received an oral formulation of the drug.

Determination of atenolol in plasma by dual-column liquid chromatography and fluorimetric detection

A simple and rapid liquid chromatographic method for the determination of atenolol in plasma is described. Plasma proteins were precipitated with zinc sulphate and sodium hydroxide prior to injection onto a precolumn, which was connected to the analytical column by a switching valve. When atenolol was eluted onto the analytical column, the precolumn was cleaned by backflushing to eliminate strongly retained endogenous compounds. The atenolol fluorescence was measured after excitation at 197 nm. The limit of quantitation in plasma was 15 ng/ml. The within-day precision of atenolol was 1.6% at a level of 210 ng/ml, 5.0% at 25 ng/ml and the between-day precision was 3.3% at 50 ng/ml.

Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man

Chronic coadministration of oral verapamil with oral atenolol resulted in a variable increase in atenolol steady-state plasma concentrations in a group of 10 patients on chronic maintenance therapy. Individual subjects showed changes in area under the plasma atenolol concentration-time curve (AUC) of more than 100%, however group comparisons did not achieve statistical significance unless normalized for verapamil dose. Renal clearance of atenolol was shown to be decreased by more than 25% in 2 subjects studied using intravenous dosing of atenolol. This interaction is likely to contribute to the documented clinical intolerance of combinations of atenolol and verapamil.

Retention behaviour of acidic, neutral and basic drugs on a CN column using phosphate buffers in the mobile phase

The retention behaviour of a set of sixteen more or less drugs on a CN column with methanol-phosphate buffer as eluent was studied. The influence of the volume percentage of methanol, pH and the ionic strength on the capacity factors (k') of the drugs was determined using an experimental design consisting of three pH values (3, 5 and 7), four ionic strengths (0.025, 0.05, 0.075 and 0.1) and three volume percentages of methanol (10, 30 and 50%). The selected drugs were basic, acidic and neutral compounds with different polarity properties. The number of carbon atoms, considered here as reflecting the hydrophobic characteristics of the solutes, varied from 7 to 25. The influence on the retention of drugs on a CN column of the different parameters studied was evaluated. The volume percentage of organic modifier and the pH are the most important factors. A change in ionic strength is important only when large molecules are chromatographed. As the interaction between pH, ionic strength and volume percentage of methanol is small, optimization of the three parameters separately is possible.

Determination of metoprolol and two major metabolites in plasma and urine by column liquid chromatography and fluorometric detection

Metoprolol and its alpha-hydroxy metabolite were determined in plasma down to 2 nmol/l (S.D. 10-15%) after solvent extraction and bonded-phase liquid chromatography with fluorometric detection. The major metabolite with a carboxylic function was also measured in plasma when liquid-solid extraction on a column activated with dodecyl sulphate was applied. In urine the three components were assayed by direct injection of a diluted sample.

Selective manipulation of neurohumoral control of the cardiac pacemaker by drugs given intrapericardially

A technique of intrapericardial administration of beta-adrenoceptor and muscarinic cholinergic receptor antagonist drugs has been tested in conscious rabbits. Intrapericardial propranolol or atenolol (50 micrograms/kg) had the same effect on isoprenaline heart rate dose-response curves and on the sympathetic component of the arterial baroreceptor-heart rate reflex as did conventional, 5-fold greater, intravenous doses of the drugs. The action of intrapericardial propranolol was attributable to its (-)isomer. Intrapericardial propranolol (50 micrograms/kg) had little effect on ventricular contractility. Plasma levels of propranolol and atenolol after intrapericardial administration were, respectively, 7- and 40-fold less than after the usual intravenous doses. Intrapericardial hyoscine methyl bromide (10 micrograms/kg) abolished baroreflex vagal effects on heart rate as effectively as did the conventional, 5-fold greater, intravenous dose. The duration of receptor blockade by both classes of drugs when given intrapericardially was at least 2 hr. We conclude that the rapid diffusion of beta-adrenoceptor and muscarinic cholinergic receptor blocking drugs from the pericardial sac to receptors on the sinoatrial cardiac pacemaker, and their prolonged actions, provides a useful technique for preventing the actions of the sympathetic and vagus nerves, and of circulating catecholamines, on the chronotropic functions of the heart.

Identification and differentiation of beta-blockers and their metabolites in urine by computerized gas chromatography-mass spectrometry

A method for the identification and differentiation of beta-blockers and their metabolites in urine after acid hydrolysis is described. The acetylated extract is analysed by computerized gas chromatography-mass spectrometry. An on-line computer allows rapid detection using ion chromatography with the ions of m/z 72, 86, 98, 140, 151, 159, 200 and 335. The identity of positive signals in the reconstructed ion chromatogram is confirmed by a comparison of the stored entire mass spectra with the reference spectra. The ion chromatogram, the reference mass spectra and the gas chromatographic retention indices (OV-101) are documented. References for the quantitation of the single beta-blockers are cited.

Rapid and simultaneous extraction of propranolol, its neutral and basic metabolites from plasma and assay by high-performance liquid chromatography

A high-performance liquid chromatographic method is described for the determination of propranolol, its neutral and basic metabolites from a single plasma sample. These analytes were extracted simply and efficiently by a solid-phase extraction column based on C18 modified silica (C18 Bond-Elut). Propranolol, the 4-hydroxy and N-desisopropyl metabolites were separated on a mu Bondapak C18 column with a mobile phase of acetonitrile--0.1% phosphoric acid. Propranolol glycol was selectively eluted from the C18 Bond-Elut column with acetonitrile and chromatographed separately with a mobile phase of acetonitrile--water. The recoveries of propranolol and all metabolites were greater than 78% with an intra-assay coefficient of variation between 4.9 and 7.3% at a concentration of 5-50 ng/ml. The minimum detectable levels in 1 ml of plasma were 1.0 ng/ml propranolol, 6.0 ng/ml 4-hydroxypropranolol, 1.0 ng/ml N-desisopropylpropranolol and 2.5 ng/ml propranolol glycol. Enzyme hydrolysis, Bond-Elut extraction and high-performance liquid chromatography revealed that propranolol, the neutral and basic metabolites were extensively conjugated in dog plasma (propranolol 67%, 4-hydroxypropranolol 98%, N-desisopropylpropranolol 55% and propranolol glycol 80%). With the use of pure enzymes and a selective inhibitor the nature of this conjugation appeared to involve both glucuronidation and sulfation. The conjugation of propranolol involved mainly glucuronidation (58-62%) compared to sulfation (7-12%), whilst that of 4-hydroxypropranolol mainly involved sulfation (55-65%) compared to glucuronidation (32-38%). The values for N-desisopropylpropranolol and propranolol glycol were 26-31% and 12% sulfation, 16-29% and 68-85% glucuronidation, respectively.